Raven Biotechnologies

Raven Biotechnologies
South San Francisco, Calif.
Founded: 1999

Why It's Fierce: Raven is identifying antibody drug targets that are overlooked by most research techniques. The company's technology accounts for cellular interactions, offering researchers a more accurate technique for pairing monoclonal antibodies with specific antigens on the cell surface. With $40 million in fresh financing, Raven has the financial resources to fund human studies of its lead products.

What to look for in 2003: The company will announce its first clinical development candidates over the coming months.

Raven Biotechnologies

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.